Profusa Partners with NVIDIA to Develop AI-Powered Continuous Biomarker Monitoring Portal
核心洞察
Profusa (搜索) announces partnership with NVIDIA (搜索) to build an AI-driven insight portal combining Lumee (搜索) oxygen monitoring sensors with NVIDIA NeMo technology for continuous biochemistry monitoring.
The physician portal will feature agentic clinical workflows powered by large language models, integrating with EMRs and wearables to assist with patient care decisions and remote monitoring.
The company plans an early 2026 rollout in the European Economic Area, aiming to provide real-time biochemistry data that links therapeutic decisions with patient outcomes.
Profusa (搜索), Inc. (Nasdaq: PFSA), a commercial-stage digital health company, announced on September 11, 2025, its adoption of NVIDIA (搜索) technology to power an AI-driven insight portal for continuous biochemistry monitoring. The Berkeley, California-based company plans to combine its Lumee (搜索) oxygen monitoring platform with NVIDIA NeMo hardware and software stack to create what it describes as an "AI-fueled, scalable technology backbone" for personalized healthcare monitoring.
AI-Powered Clinical Workflows
The physician portal will feature several advanced capabilities designed to enhance clinical decision-making. The system will include agentic clinical workflows powered by large language model (LLM) technology that integrates with electronic medical records (EMRs), wearables, and home devices. According to the company, this assistant will help clinicians with notes, orders, care plans, remote physiologic monitoring (RPM), remote therapeutic monitoring (RTM), triage, and escalations.
"We believe that real-time biochemistry data across a large population is a data-set that is currently missing to enable the fulfillment of the promise of AI-enabled improvement in healthcare," said Ben Hwang, Ph.D., Profusa (搜索)'s Chairman and CEO. "Profusa is uniquely positioned to provide this proprietary data set, linking therapeutic decisions with real-time biochemistry changes, to generate valuable insights that are lacking today."
Technical Infrastructure and Safety Features
The portal incorporates several technical safeguards and monitoring capabilities. Built-in experimentation and metrics will assess assistant quality, drift, and safety over time. The system includes policy-aware orchestration designed to enforce clinical scope, data privacy, and safe responses across patient and provider experiences.
The platform offers flexible model training options, ranging from parameter-efficient tuning to post-training refinement of Profusa (搜索)'s AI signal processing and clinical reasoning components. A key feature is the time-aligned health data graph, which provides a longitudinal view that fuses Profusa biomarkers with EMR data including problems, medications, laboratory results, vital signs, imaging, notes, claims and pharmacy data, wearables and IoT devices, genomics, and social determinants of health.
Lumee Technology Integration
The AI portal will work in conjunction with Profusa (搜索)'s Lumee (搜索) oxygen optical hydrogel sensors and reader system. These tissue-integrated sensors are designed to detect and continuously transmit medical-grade data for both personal and clinical use. The company describes its biosensors as long-lasting, injectable, and affordable, aimed at providing personalized biochemical signatures that clinicians can trust.
"We believe physicians need trustworthy, always-on insights, not more dashboards," Dr. Hwang explained. "Our intention is for this cutting-edge portal technology to answer this need by translating raw optical signals into reliable biometrics, providing actionable clinical context."
Market Launch Timeline
Profusa (搜索) expects to roll out the portal in early 2026 in the European Economic Area (EEA), which includes the European Union, Liechtenstein, Norway, and Iceland. The EEA market accepts the CE Mark for medical device approval, providing the company with regulatory pathway for commercialization.
The portal extends Profusa (搜索)'s AI-enabled signal processing and care team tools from clinician offices to remote patient monitoring settings, potentially expanding the reach of continuous biochemistry monitoring beyond traditional healthcare facilities.
Company Background
Founded in Berkeley, California, Profusa (搜索) positions itself as a pioneer in next-generation technology platforms for continuous monitoring of individual biochemistry. The company is led by what it describes as visionary scientific founders, an experienced management team, and a world-class board of directors. Profusa's technology platform focuses on developing tissue-integrated sensors that can provide continuous, actionable medical-grade data.